243 patents
Utility
Methods of administering solriamfetol to lactating women
16 Jan 24
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 24 May 23
Utility
Methods of administering solriamfetol to lactating women
16 Jan 24
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 24 May 23
Utility
Methods and compositions for treating excessive sleepiness
9 Jan 24
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
Filed: 12 May 23
Utility
Pharmaceutical compositions comprising meloxicam
9 Jan 24
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 1 Nov 22
Utility
Microparticles Containing Bupropion
4 Jan 24
This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 μm to about 100 μm.
Herriot Tabuteau
Filed: 31 Jan 23
Utility
Methods of providing solriamfetol therapy to subjects with impaired renal function
2 Jan 24
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 22 Jun 23
Utility
Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion
28 Dec 23
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms.
Herriot Tabuteau
Filed: 5 Sep 23
Utility
Treatment of Cataplexy
28 Dec 23
The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Filed: 19 Jun 23
Utility
Methods of providing solriamfetol therapy to subjects with impaired renal function
12 Dec 23
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 31 Mar 23
Utility
Methods of providing solriamfetol therapy to subjects with impaired renal function
12 Dec 23
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 31 Mar 23
Utility
Pharmaceutical compositions comprising meloxicam
28 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 29 Mar 23
Utility
Pharmaceutical compositions comprising meloxicam
28 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 7 Dec 22
Utility
Pharmaceutical Compositions Comprising Meloxicam
23 Nov 23
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and 2a) according to the patient, is never or rarely comfortable enough with the patient's migraine medication to be able to plan daily activities, 2b) according to the patient, after taking migraine medication, the patient never or rarely feels in control of the patient's migraines enough so that the patient feels there will be no disruption in the patient's daily activities, 2c) has an mTOQ-4 score of 0, and/or 2d) has a history of depression; and administering a combination of 20 mg of meloxicam and 10 mg of rizatriptan to the patient during a migraine attack.
Herriot Tabuteau
Filed: 24 May 23
Utility
Pharmaceutical Compositions Comprising Meloxicam
9 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 6 Jul 23
Utility
Pharmaceutical compositions comprising meloxicam
7 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 2 Sep 22
Utility
Pharmaceutical compositions comprising meloxicam
31 Oct 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 2 Sep 22
Utility
Pharmaceutical Compositions Comprising Meloxicam
26 Oct 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 20 Jun 23
Utility
Methods of administering solriamfetol to lactating women
24 Oct 23
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 1 Mar 23
Utility
Dosage forms and methods for enantiomerically enriched or pure bupropion
17 Oct 23
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms.
Herriot Tabuteau
Filed: 10 Mar 22
Utility
Carbamoyl phenylalaninol compounds and uses thereof
10 Oct 23
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
Fionn Hurley, Lawrence Patrick Carter
Filed: 9 Sep 21